# Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

> **NCT06435845** · PHASE2 · TERMINATED · sponsor: **Rallybio** · enrollment: 1 (actual)

## Conditions studied

- Fetal and Neonatal Alloimmune Thrombocytopenia

## Interventions

- **DRUG:** Anti-(integrin beta-3) human monoclonal antibody

## Key facts

- **NCT ID:** NCT06435845
- **Lead sponsor:** Rallybio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-11-21
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** This study was terminated early by the sponsor due to insufficient drug exposure to achieve the intended therapeutic effect.
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06435845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06435845, "Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06435845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*